Use of dipolymer of phthalide

A composition and technology of anti-tumor drugs, applied in the application field of preparing anti-tumor drug compositions, can solve problems such as toxic side effects, limited clinical application, etc., achieve fast effect, enhanced killing of tumor cells, and multi-drug resistance Sex-reducing effect

Active Publication Date: 2005-10-12
JIANGSU MICRODIAG BIOMEDICINE TECH CO LTD
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the known reversal agents have obvious toxic and side effects when they revers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of dipolymer of phthalide
  • Use of dipolymer of phthalide
  • Use of dipolymer of phthalide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1: Isolation and identification of LA

[0035] The process steps of separating and purifying compound LA from Chuanxiong or Angelica can be found in figure 1 flow chart.

[0036] The separation method of LA can be found in the articles of wang PS et al. (Phytochemistry 1984; 23; 2033-8 and Chinese Pharmaceutical Industry 1988; 19:553-9) or Kaouadji M et al. (J Nat Prod 1986; 49:872-7) and Naito Two articles by T et al. (Heterocycles 1991; 32: 2433-42).

[0037] The invention according to figure 1 The process steps obtained from Rhizoma Chuanxiong are colorless and transparent crystals, which are identified by LC-MS and HNMR. The real-time chromatographic data of LC-MS detected by chuanxiong extract at 294nm Figure 2A and Figure 2B .

[0038] Embodiment 2-7 is to the cytological utility evaluation of compound LA

[0039] Among them, the cell lines used are k562 (human chronic myelogenous leukemia cell line) and k562 / adr (k562 cell line resistant to chemo...

Embodiment 2

[0044] Example 2: Measuring the main drug resistance mechanism of each drug-resistant strain

[0045] Collect cultured 5×10 6 K562, k562 / adr, kb, kbv200 cells were washed twice with PBS, followed by the instructions of the P-gp fluorescent antibody kit (UIU2), and FACS was performed to detect the expression of P-gp, and 10,000 cells were counted for each sample.

[0046]The determination results of the main drug resistance mechanism of each drug-resistant strain:

[0047] k562: P-gp expression 1.02%; k562 / adr: P-gp high expression up to 83.6%;

[0048] kb: P-pg expression was 0.87%; kbv200: P-gp was highly expressed to 76.3%.

[0049] The above experiments proved that the main drug resistance mechanism of the two drug-resistant cell lines k562 / adr and kbv200 was overexpression of P-pg, while the expression of p-gp in the sensitive strains was negative.

Embodiment 3

[0050] Embodiment 3: Measuring the multiples of drug resistance of each drug-resistant strain to doxorubicin and vincristine

[0051] 1).k562 / adr cell line

[0052] Take cells in the logarithmic growth phase, use RPMI1640 culture medium containing 10% calf serum to make cell suspension, add 100ul per well to a 96-well plastic culture plate, so that the number of cells per well is 2×10 4 After 30 minutes, add 100ul chemotherapeutic drugs doxorubicin and vincristine according to the concentration gradient of 0, 0.01, 0.1, 0.5, 1, 5, 10, and 20ug / ml respectively. The volume is 200ul, and the insufficient part is made up with RPMI 1640, placed in a carbon dioxide incubator, 37°C, saturated humidity, 5% CO 2 cultured under the condition of CO 2 conditions for 68 hours. Add 50ul of MTT (2mg / ml) to each well to remove the supernatant, add 120ul of DMSO to each well, oscillate with a micro-oscillator to fully dissolve the drug, and detect the OD value at 590nm wavelength by Elisa. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of the phenyl phthaleine dipolymer Levistolide A (LA) in preparing antineoplastic medicines is disclosed. Said compound features broad spectrum, high effect to kill cancer cells and low toxic by-effect to cardiovascular system and immune system.

Description

technical field [0001] The invention relates to the application of a phthalide dimer and the compound Levistolide A (LA) in the preparation of an antitumor drug composition. Background technique [0002] Tumor multidrug resistance (multidrug resistance, MDR) is an important reason for the failure of chemotherapy. Multidrug resistance refers to the cross-resistance of tumor cells to various anticancer drugs with different chemical structures, functions and mechanisms of action. In a sense, 90% of cancer deaths are related to primary or acquired drug resistance. [0003] The mechanism causing MDR is relatively complicated, but the overexpression of the main "drug pump" P-gp protein on the tumor cell membrane is an important cause of MDR. The product of mdr1 gene, P-gp (p-glycoprotein), is a transmembrane glycoprotein that reduces the accumulation of cytotoxic drugs in cells through an energy-dependent mechanism and acquires multidrug resistance. Solid tumors, including colo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/365A61P35/00
Inventor 陈菲王弢吴一峰张弘钱凯先
Owner JIANGSU MICRODIAG BIOMEDICINE TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products